January 12, 2021 5:25pm

“Learn to pick the right wave, investors, all waves are NOT the same: the bigger, the better” and fine tune the peaks, periods of time and swells

Numbers based facts speak better then opinion as I see answers in numbers

Pre-open indication: 4 HITs and 2 MISS

Are we here to make money or see it erode as sessions evolve?  Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting!

The Dow closed UP +60 points (+0.19%); the S&P closed UP +1.58 points (+0.04%) while the Nasdaq closed UP +36 points (+0.28%)



Indexes are fluttering back negative and forth positive – closing to the upside as traders weighed rising interest rates as economic recovery is shuttered from the coronavirus pandemic.

As social media companies share pricing falls, the RegMed/Stem/Cell and gene therapy sector appears to be a safer haven.


Sentiment and COVID-19 infections:

The U.S. vaccine rollout is beginning to pick up steam. Nearly 9 million doses have been administered across the country as of Monday morning, according to CDC data. That’s an increase of more than 2 million in a single day. Though the pace appears to be improving, administered vaccine doses still represent only about a third of total doses distributed to states so far. <CNBC>

Infection cases <Million>: never to forget …

  • Monday 22.62 M cases,
  • Monday’s death rate totaled 376,695 <Johns Hopkins University>


This a.m.’s post, “what’s motivating markets? Momentum and sentiment indicators are stretched yet, yesterday’s breather brought back a FOMO (fear of missing out)” … https://www.regmedinvestors.com/articles/11717


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Tuesday opened positive at 27/7 and 1 flat, stayed positive at the mid-day at 20/14 and 1 acquired, closing positive at 21/13 and 1 acquired;
  • Monday opened negative at 20/14 and 1 flat, stayed negative at the mid-day at 12/20 and 3 flat3, closing negative at 13/20, 1 flat and 1 acquired;
  • Friday opened positive at 20/14 and 1 flat, dived negative at the mid-day to 826 and 1 flat, closing negative at 16/18 and 1 acquired;


Pre-open indication:

  • 4 HITs <BUYS: ReNeuron (RENE.L +$13.00); Sell into Strength: Intellia Therapeutics (NTLA +$2.91); CRISPR therapeutics (CRSP +$1.46), Mesoblast (MESO -$1.16)> `2 MISS < Maintaining SELL: Biostage (BSTG +$0.08 with 3,541 shares traded <3-month average =2,268 shares – keep pumping, BUYS: Editas Medicine (EDIT -$1.94)>


Key metrics:

  • Sector volume was BALANCED with 8 of the 21-upside having higher than the 3-month average volume with the increased volume of 5 of 13-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 21-upside were +0.04% (FATE) to +12.25% RENE.L() while the 13-downside ranges from -0.77% (MDXG) to -10.18% (MESO);


There are clear winners — and losers — heading into the first month of 2021.

52-week high

  • Sage Therapeutics (SAGE) at $94.13

Hammered in today’s market:

  • Ultragenyx (RARE), Ionis Pharmaceuticals (IONS), Mesoblast (MESO), Editas Medicine (EDIT), uniQure NV (QURE) to name 5 of the 13 declining of the 35 covered

Jumping with share pricing momentum:

  • ReNeuron (RENE.L), Sage Therapeutics (SAGE), Alnylam Pharmaceuticals (ALNY), Vericel (VCEL), Intellia Therapeutics (NTLA) to name 5 of the 21 inclining of the 35 covered


Tuesday’s (10 of 21) incliners:

  • ReNeuron (RENE.L +$13.00 after Monday’s flat)
  • Alnylam Pharmaceuticals (ALNY +$9.02 after Monday’s +$9.97);
  • Sage Therapeutics (SAGE +$3.10 after Monday’s +$0.15);
  • Intellia Therapeutics (NTLA +$2.91 after Monday’s -$5.58);
  • Vericel (VCEL +$2.51 after Monday’s -$1.28);
  • bluebird bio (BLUE +1.93 after Monday’s +$1.86);
  • CRISPR Therapeutics (CRSP +$1.46 after Monday’s -$4.94)
  • Regenxbio (RGNX +$0.61 after Monday’s +$1.17);
  • AxoGen (AXGN +$0.51 after Monday’s +$0.05);
  • Solid Biosciences (SLDB +$0.36);

Tuesday’s (13 of 13) decliners:

  • Ultragenyx (RARE -$4.10 after Monday’s -$8.85);
  • Ionis Pharmaceuticals (IONS -$2.95 after Monday’s +$1.06);
  • Editas Medicine (EDIT -$1.94 after Monday’s -$13.64);
  • uniQure NV (QURE -$1.51 after Monday’s -$1.12);
  • Mesoblast (MESO -$1.16 after Monday’s +$2.74);
  • Sangamo Therapeutics (SGMO -$0.45 after Monday’s -$0.77);
  • Adverum Biotechnologies (ADVM -$0.42 after Monday’s +$0.29);
  • BioLife solutions (BLFS -$0.34);
  • Chinook Therapeutics (KDNY -$0.27);
  • Precigen (PGEN -$0.18)
  • Pluristem (PSTI -$1.18 after Monday’s +$1.08);
  • Bellicum Pharmaceuticals (BLCM -$0.13 after Monday’s +$0.27);
  • MiMedx (MDXG -$0.07);

Closing 1 -Stemline Therapeutics (STML – acquired)



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +0.25% and XBI closed up +0.87%
  • Monday, the IBB closed down -0.16% and XBI closed down -0.99%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.75 points or -3.11% at 23.33
  • Monday was up +2.52 points or +11.69% at 24.08

Upside volume:

  • Tuesday: 8 out of the 21-upside had higher than the 3-month average volume;
  • Monday: 5 out of the 13-upside had higher than the 3-month average volume;

Downside volume:

  • Tuesday: 5 out of the 13-downside had higher than the 3-month average volume;
  • Monday: 10 out of the 20-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Tuesday’s percentage (%) of the 21-upside were +0.04% (FATE) to +12.25% RENE.L() while the 13-downside ranges from -0.77% (MDXG) to -10.18% (MESO);
  • Monday’s percentage (%) of the 13-upside were +0.17% (SAGE) to +31.64% (MESO) while the 20-downside ranges from -0.62% (CLBS) to -15.06% (EDIT);


January, the 1st month of Q1 …

Tuesday closed positive with 21 advancers, 13 decliners and 1 flat

Monday (1/11) closed negative with 13 advancers, 20 decliners and 2 flats

Friday closed negative with 16 advancers, 18 decliners and 1 flat

Thursday closed positive with 31 advancers, 2 decliners and 2 flats

Wednesday closed positive with 22 advancers, 12 decliners and 1 flat

Tuesday closed positive with 19 advancers, 14 decliners and 2 flats

Monday (1/4) closed positive with 26 advancers, 7 decliners and 2 flats


The Bottom Line: there is a short-term tone shift in the market; reiterating, “Sector volatility remains fluid … as I had stated, “you should take some profits even if some money is left on the table – safety is cash in your pocket of portfolio!”

Right again … Sell the highs and grab the dips!

Never forget, the “hungry” Pac-man algorithms satiate as the sector soared!

Earnings LPS (los-per-share) season is coming quickly!!


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.